Clinical trials: Hematological Malignancies
Acute Kidney Injury, Drug Toxicity
Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate
This retrospective observational study will evaluate high-dose methotrexate patterns of use, supportive care measures used during high-dose methotrexate chemotherapy, along with the incidence of delayed elimination of…
- Trial name
- NCT05899751
- Testing
- High-dose methotrexate, Glucarpidase
- Where
- 5 sites in France, Italy and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Protherics Medicines Development Limited
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia
- Trial name
- Orca-T (NCT05316701)
- Testing
- Orca-T, Standard-of-Care
- Where
- 19 sites in United States
- Volunteers
- 187 people
- Sponsor
- Orca Biosystems, Inc.
Invasive Fungal Infections
Revision of Antifungal Strategies Definitions for Invasive Fungal Infections in Hematological Malignancies
The primary objective of this study is to evaluate invasive fungal infections (IFI) according to clinicians' opinion vs the opinion of an independent board of experts.
- Trial name
- NCT04024995
- Where
- 14 sites in Italy
- Volunteers
- 513 people
- Sponsor
- Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne
Chimeric Antigen Receptor T-cell Therapy, Hematologic Malignancy
Symptom Monitoring and Management Intervention After CAR-T
The goal of this study is to refine and test a digital intervention named WAYPOINT to help patients monitor and manage symptoms after CAR-T therapy.
- Trial name
- APPROACH (NCT07886190)
- Testing
- WAYPOINT
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Solid Tumor, Hematologic Malignancy
GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
Immune checkpoint blockade has made great but unsatisfied success in treating cancers. One important reason is the hijacked HLA (Human Leukocyte Antigen) antigen presentation.
- Trial name
- NCT04944888
- Testing
- Eliglustat, Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Chinese PLA General Hospital
Thrombocytopenia
Collection of Peripheral Blood From Patients With Hematologic Malignancies With Thrombocytopenia
The purpose of the research project is to collect one blood sample from participants who are affected by very low platelets as a result of their condition or their treatment.
- Trial name
- NCT06824727
- Testing
- Baseline cell blood counts
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Case Comprehensive Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression
This phase I trial evaluates the best dose and side effects of copper (64Cu)-DOTA-pembrolizumab positron emission tomography (PET) for the study of PD1 expression.
- Trial name
- NCT04605614
- Testing
- Copper Cu 64-DOTA-pembrolizumab, Pembrolizumab, Positron Emission Tomography
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemias, Advanced Hematological Malignancies
Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells
Experimental and clinical data suggest that alloreactive NK cells can reduce the risk of graft-rejection, GvHD and leukemic relapse after HLA-mismatched transplantation.
- Conditions
- Acute Myeloid Leukemias, Advanced Hematological Malignancies, Indication for Allogeneic Stem Cell Transplantation, no HLA-identical Donor Available
- Trial name
- NCT01220544
- Testing
- Haploidentical transplantation with donor NK cells
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Charite University, Berlin, Germany
Blood Cancer, Multiple Myeloma
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Mixed chimerism transplantation is an approach to allogeneic transplants that attempts to decrease regimen-related toxicity by using non-myeloablative preparatory regimens; establish mixed chimerism using low dose total body…
- Trial name
- NCT00185614
- Testing
- Autologous hematopoietic cell transplant (Auto-HCT), Allogeneic hematopoietic cell transplant (Allo-HCT), Cyclophosphamide
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Wen-Kai Weng
Hematologic Malignancy
B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematological malignancies.
- Trial name
- B-REC (NCT04682314)
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematological Malignancies
An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation
The 'Open Window' Study is a prospective longitudinal study using a 4 group randomised control trial design to evaluate the psychological effect of 'Open Window' on the consequences of long term isolation on patients undergoing…
- Trial name
- NCT00348959
- Testing
- 'Open Window' Project
- Where
- Ireland
- Volunteers
- 198 people
- Sponsor
- St. James's Hospital, Ireland
Blood Cancer, Multiple Myeloma (MM)
Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer
Research into cancer patients has shown that quality of life is significantly altered by the disease and its associated treatments and is also reported to be a predictor of significant emotional distress.
- Conditions
- Blood Cancer, Multiple Myeloma (MM), Lymphoma
- Trial name
- NCT06817759
- Testing
- Virtual Reality Hypnosis, VRH : Beach, VRH : Forest
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Hematologic Malignancies
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
In this trial, we aim to improve the outcomes of haplo cord transplant. Haplo cord transplant is a novel and promising way to improve transplant outcomes.
- Trial name
- NCT01810588
- Testing
- CliniMACS® CD34 Reagent System, Fludarabine, Melphalan
- Where
- 2 sites in United States
- Volunteers
- 270 people
- Sponsor
- Weill Medical College of Cornell University
Non-hematological Malignancies
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from non-hematological malignancies with Chemotherapy induced anaemia.
- Trial name
- PK-CIA-04 (NCT01213979)
- Testing
- 500 mg iron isomaltoside 1000, 1000 mg iron isomaltoside 1000
- Volunteers
- 16 people
- Sponsor
- Pharmacosmos A/S
Graft Versus Host Disease, Hematologic Malignancies
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
The main purpose of this study is to evaluate the effect of palifermin versus placebo in the reduction of severe acute graft versus host disease (GVHD) and severe oral mucositis.
- Trial name
- NCT00189488
- Testing
- Palifermin, Conditioning Regimen, Allogeneic stem cell transplant
- Volunteers
- 155 people
- Sponsor
- Swedish Orphan Biovitrum
Relapsed or Refractory Multiple Myeloma
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and…
- Trial name
- ARROW2 (NCT03859427)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 108 sites in United States, Austria and 15 more
- Volunteers
- 454 people
- Sponsor
- Amgen
Multiple Myeloma, Waldenstrom Macroglobulinemia
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
The purpose of this study is to determine the maximum tolerated dose (MTD), activity, and safety of oprozomib in patients with hematologic malignancies.
- Trial name
- NCT01416428
- Testing
- oprozomib
- Where
- 19 sites in United States
- Volunteers
- 210 people
- Sponsor
- Amgen
Multiple Myeloma (MM), Hematologic Neoplasm
Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers
Individuals with multiple myeloma (MM) are vulnerable because of the effects of systemic organ damage and the side effects of treatment.
- Trial name
- MMYLIFE (NCT07014865)
- Where
- Italy
- Volunteers
- 190 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Leukemia
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
The purpose of this study was to determine the efficacy and safety of twice daily (bid) oral midostaurin in patients with Aggressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia (MCL) with or without an Associated…
- Trial name
- NCT00782067
- Testing
- Midostaurin (PKC412)
- Where
- 29 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT02862275
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 9 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.